29 April 2025

Spotlight Pathology raises £425k led by EHE Ventures to advance AI diagnostic tools

EHE Ventures led the round with support from Deepbridge Capital and Lyva Labs to accelerate product development and regulatory approval.

£425K

Spotlight Pathology is a medical technology company developing artificial intelligence tools to assist clinicians in diagnosing blood cancers. Its platform uses proprietary computer vision models to streamline lymph node and bone marrow biopsy workflows.

Spotlight Pathology has secured £425k in funding led by EHE Ventures, with participation from Deepbridge Capital and Lyva Labs. The capital will enable the medical technology company to complete its artificial intelligence platform development, obtain UKCA regulatory approval, and launch pilot programmes across the UK, Europe, and the US.

The investment forms part of an anticipated £1.1m round scheduled to close later in the year. EHE Ventures contributed via its AI Growth Fund, alongside continued support from Deepbridge Capital, which previously backed the firm through its Seed Enterprise Investment Scheme.

From the founder

"There’s a critical shortage of pathologists, and the stakes are high—delayed diagnosis means delayed treatment. Our platform gives clinicians the tools to confidently streamline diagnostic workflows."

Sam Perona

CEO at Spotlight Pathology

Investor perspective

"Spotlight Pathology represents exactly the type of highly innovative company that Deepbridge is privileged to invest in. We initially supported the team through our Seed Enterprise Investment Scheme (SEIS), and are now pleased to back them again through our EIS fund, alongside EHE and Lyva Labs. We look forward to supporting the team as they scale in the exciting field of digital pathology."

Andrew Round

Investment Director, Deepbridge Capital

Use of funds

01Continue product development
02Expand into international markets

Investors

Neil Vose

EHE Ventures

Andrew Round

Deepbridge Capital

Lyva Labs

About the company